Three generations of ADC: Nearly a decade of development-PI
Antibody-drug conjugate (ADC: https://www.creative-biolabs.com/adc/), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized 13 ADC drugs for marketing, with hundred